Header Logo

Connection

Patrick Arbuthnot to Gene Silencing

This is a "connection" page, showing publications Patrick Arbuthnot has written about Gene Silencing.
Connection Strength

3,093
  1. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses. 2020 08 04; 12(8).
    View in: PubMed
    Score: 0,709
  2. Generating DNA Expression Cassettes Encoding Multimeric Artificial MicroRNA Precursors. Methods Mol Biol. 2020; 2115:185-197.
    View in: PubMed
    Score: 0,680
  3. Use of guanidinopropyl-modified siRNAs to silence gene expression. Methods Mol Biol. 2015; 1218:217-49.
    View in: PubMed
    Score: 0,481
  4. Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses. 2006 May; 22(5):401-10.
    View in: PubMed
    Score: 0,264
  5. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
    View in: PubMed
    Score: 0,126
  6. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter. Biomed Res Int. 2014; 2014:718743.
    View in: PubMed
    Score: 0,116
  7. Construction of effective inverted repeat silencing constructs using sodium bisulfite treatment coupled with strand-specific PCR. Biotechniques. 2012 Apr; 52(4):254-62.
    View in: PubMed
    Score: 0,099
  8. Countering hepatitis B virus infection using RNAi: how far are we from the clinic? Rev Med Virol. 2011 Nov; 21(6):383-96.
    View in: PubMed
    Score: 0,096
  9. MicroRNA-like antivirals. Biochim Biophys Acta. 2011 Nov-Dec; 1809(11-12):746-55.
    View in: PubMed
    Score: 0,093
  10. Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opin Drug Deliv. 2010 Dec; 7(12):1373-85.
    View in: PubMed
    Score: 0,090
  11. Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One. 2009 Sep 30; 4(9):e7232.
    View in: PubMed
    Score: 0,084
  12. Hepatic delivery of RNA interference activators for therapeutic application. Curr Gene Ther. 2009 Apr; 9(2):91-103.
    View in: PubMed
    Score: 0,081
  13. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther. 2008 Jun; 16(6):1105-12.
    View in: PubMed
    Score: 0,076
  14. In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
    View in: PubMed
    Score: 0,048
  15. Specific micro RNA-regulated TetR-KRAB transcriptional control of transgene expression in viral vector-transduced cells. PLoS One. 2012; 7(12):e51952.
    View in: PubMed
    Score: 0,026
  16. Synthesis of 2'-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus. Bioorg Med Chem. 2012 Feb 15; 20(4):1594-606.
    View in: PubMed
    Score: 0,024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.